Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 6—June 2023
Dispatch

Results of PCR Analysis of Mpox Clinical Samples, Sweden, 2022

Jon Edman-Wallér1Comments to Author , Ola Jonsson1, Gustav Backlund1, Shaman Muradrasoli, and Klara Sondén
Author affiliations: Sahlgrenska University Hospital, Gothenburg, Sweden (J. Edman-Wallér); University of Gothenburg Institute of Biomedicine, Gothenburg (J. Edman-Wallér); Linköping University Hospital, Linköping, Sweden (O. Jonsson); Falu Hospital, Falun, Sweden (S. Muradrasoli); Public Health Agency of Sweden, Solna, Sweden (S. Muradrasoli, K. Sondén); Karolinska Institute Department of Medicine, Solna (K. Sondén)

Main Article

Figure 2

Mpox PCR Ct values in skin lesion samples and days since onset of signs (day 1) analyzed at the Public Health Agency of Sweden, May 24–Sep 2, 2022 (n = 83). Gray lines connect samples from the same patient. Blue line (smoothing spline) is for visualization.

Figure 2. Mpox PCR Ct values in skin lesion samples and days since onset of signs (day 1) analyzed at the Public Health Agency of Sweden, May 24–Sep 2, 2022 (n = 83). Gray lines connect samples from the same patient. Blue line (smoothing spline) is for visualization.

Main Article

1These authors contributed equally to this article.

Page created: March 20, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external